Hussman Strategic Advisors’s PTC Therapeutics PTCT Stock Holding History

Hussman Strategic Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.57M	Buy	+31,500	New	+$2.27M	0.59%	68
2026 Q1	–	Sell	-25,200	Closed	-$1.91M	–	321
2025 Q4	$1.91M	Sell	25,200 -37,800	-60%	-$2.75M	0.46%	97
2025 Q3	$3.87M	Hold	63,000	–	–	0.84%	9
2025 Q2	$3.08M	Buy	63,000 +42,000	+200%	+$1.99M	0.7%	45
2025 Q1	$1.07M	Hold	21,000	–	–	0.26%	158
2024 Q4	$948K	Buy	+21,000	New	+$899K	0.28%	142
2019 Q2	–	Sell	-50,000	Closed	-$1.88M	–	237
2019 Q1	$1.88M	Hold	50,000	–	–	0.46%	93
2018 Q4	$1.72M	Buy	50,000 +15,000	+43%	+$539K	0.41%	110
2018 Q3	$1.65M	Sell	35,000 -15,000	-30%	-$621K	0.48%	95
2018 Q2	$1.69M	Buy	+50,000	New	+$1.56M	0.45%	98

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Hussman Strategic Advisors's PTCT Position: Q2 2026 in Review

Hussman Strategic Advisors opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 31,500 shares worth $2.57M. The stake represents 0.59% of the portfolio and ranks #68 among its holdings. This is a return to the name: Hussman Strategic Advisors previously reported a position in PTCT as recently as Q4 2025.

Hussman Strategic Advisors first reported a position in PTCT in Q2 2018 and has held it in 10 quarters since. The position peaked at $3.87M in Q3 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Hussman Strategic Advisors held 31,500 shares of PTC Therapeutics worth $2.57M as of Q2 2026.
PTC Therapeutics was a new Hussman Strategic Advisors position in Q2 2026.
PTC Therapeutics made up 0.59% of Hussman Strategic Advisors's portfolio in Q2 2026, its #68 holding.
Hussman Strategic Advisors first reported a position in PTC Therapeutics in Q2 2018 and has held it in 10 quarters since.
Hussman Strategic Advisors's PTC Therapeutics position peaked at $3.87M in Q3 2025.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.